Non-small cell lung cancer
Conditions
Interventions
Training and validation cohort:None
Prospective cohort:None
Sponsors
Shandong First Medical University Affiliated Tumor Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign a written informed consent form and agree to comply with study-related requirements (informed consent is required for the prospective cohort; it may be waived for the retrospective cohort upon approval by the Ethics Committee). 2. Diagnosed with NSCLC, preferably confirmed by pathological or cytological examination; if the patient is unable or refuses to undergo biopsy due to comorbidities, a high clinical suspicion of primary lung cancer must be verified by a multidisciplinary expert team based on progressive enlargement of the primary lesion (evidenced by two CT scans performed 3 months apart) or high uptake of 18F-fluorodeoxyglucose (18F-FDG) on PET/CT. 3. Clinical stage ?-? (T1-2N0M0) with a tumor diameter = 6 months. 6. Completion of chest CT and PET imaging within 1 month prior to radiotherapy, with an interval of no more than 2 weeks between PET and CT scans, and the imaging data quality meets the required standards. 7. Availability of complete baseline clinical, imaging, and laboratory examination data, and ability to cooperate with full-course treatment data collection and long-term follow-up. 8. No severe hepatic or renal insufficiency, coagulation disorders, or other comorbidities that may affect the study.
Exclusion criteria
Exclusion criteria: 1. Concurrent multiple primary lung cancers or other malignant tumors (subjects with other malignant tumors cured by local treatment are allowed, such as basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, esophagus, or breast, etc.). 2.Previous receipt of any form of anti-tumor therapy. 3.Presence of severe underlying lung diseases (e.g., severe chronic obstructive pulmonary disease, pulmonary fibrosis) or active infectious diseases. 4. Poor quality of imaging data (such as severe motion artifacts, substandard scanning parameters) or inability to cooperate with designated imaging examinations. 5. Severe data missing or inability to cooperate with long-term follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Area Under the Curve (AUC); Sensitivity;Specificity;Accuracy (ACC); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Countries
China
Contacts
Public ContactMeng Xiangjiao
Shandong First Medical University Affiliated Tumor Hospital (Shandong Provincial Tumor Hospital)
Outcome results
None listed